Featured Research

from universities, journals, and other organizations

UCSD Researchers Use Gene Therapy To Promote Recovery From Spinal Cord Injuries

Date:
July 16, 1997
Source:
University Of California, San Diego
Summary:
Researchers from the UCSD School of Medicine report the first successful use of gene therapy to achieve partial recovery from spinal cord injuries.

FOR RELEASE: TUESDAY, JULY 15 (A.M.s)

Media Contact: Nancy Stringer,(619) 543-6163

UCSD RESEARCHERS USE GENE THERAPY TO PROMOTE RECOVERY FROM SPINAL CORD INJURIES

Researchers from the UCSD School of Medicine report the first successful use of gene therapy to achieve partial recovery from spinal cord injuries.

In studies involving laboratory rats, gene therapy was used to stimulate the regrowth of damaged axons by changing the function of an injured animal's cells allowing them to produce a growth factor directly at the site of injury.

"This novel use of gene therapy provides the opportunity for injured axons to regenerate through the spinal cord and restore function," said Mark H. Tuszynski, M.D., Ph.D., associate professor of neurosciences at the UCSD School of Medicine and a neurologist at the Veterans Affairs Medical Center in San Diego.

The findings appear in the July 15 issue of The Journal of Neuroscience.

Axons are the "wires" that cells use to communicate with one another as they relay messages from the brain. Injured adult mammal spinal cords show little spontaneous recovery after injury often leading to paralysis.

In previous studies, Tuszynski and his colleagues have shown that injured spinal cord cells can be stimulated to regrow when exposed to certain nerve growth proteins. In the study reported today, rats with spinal cord injuries had a sample of normal skin cells removed that were cultured in the laboratory and genetically modified to produce the growth factor neurotrophin-3 (NT-3). When grafted back into the animal, the modified cells secreted NT-3 at the site of spinal cord injury, which in turn stimulated axon regrowth and resulted in some recovery of walking ability.

In addition, the genetically modified cells were also found to deliver NT-3 continuously for several months, further enhancing the regeneration of injured axons and the partial restoration of function.

"The goal in spinal injury research is to promote the regrowth of cut or damaged axons," said Tuszynski. "These results indicate that cellular delivery of NT-3 through gene therapy can restore function by promoting the sustained growth of axons after spinal cord injury."

Individuals contributing to the study included Ray Grill, Ph.D.; Keith Mural; Fred Gage, Ph.D., and Armin Blesch, Ph.D. This work was supported by the Hollfelder Foundation, International Spinal Research Trust, and Veterans Affairs Research.

# # #


Story Source:

The above story is based on materials provided by University Of California, San Diego. Note: Materials may be edited for content and length.


Cite This Page:

University Of California, San Diego. "UCSD Researchers Use Gene Therapy To Promote Recovery From Spinal Cord Injuries." ScienceDaily. ScienceDaily, 16 July 1997. <www.sciencedaily.com/releases/1997/07/970716025152.htm>.
University Of California, San Diego. (1997, July 16). UCSD Researchers Use Gene Therapy To Promote Recovery From Spinal Cord Injuries. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1997/07/970716025152.htm
University Of California, San Diego. "UCSD Researchers Use Gene Therapy To Promote Recovery From Spinal Cord Injuries." ScienceDaily. www.sciencedaily.com/releases/1997/07/970716025152.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins